STOCK TITAN

Acasti Pharma, Inc. - $ACST STOCK NEWS

Welcome to our dedicated page for Acasti Pharma news (Ticker: $ACST), a resource for investors and traders seeking the latest updates and insights on Acasti Pharma stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Acasti Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Acasti Pharma's position in the market.

Rhea-AI Summary
Acasti Pharma has announced that WuXi Clinical Development will conduct the Phase 3 safety trial for GTX-104, its novel nimodipine formulation for aSAH. The trial will evaluate the drug's safety and tolerability profile in comparison to oral nimodipine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.62%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.86%
Tags
none
-
Rhea-AI Summary
Acasti Pharma announces alignment with FDA on Phase 3 trial protocol for GTX-104 and potential NDA package
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.23%
Tags
Rhea-AI Summary
Acasti Pharma announced financial and operational results for the fiscal year ended March 31, 2023. Highlights include confirmation of regulatory pathway for GTX-104, submission of Phase 3 Safety Study protocol to FDA, implementation of strategic transformation, extension of cash runway, and evaluation of strategic alternatives. Cash, cash equivalents, and short-term investments totaled $27.9 million as of March 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.75%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.85%
Tags
conferences
-
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.17%
Tags
management
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.33%
Tags
management
Acasti Pharma, Inc.

Nasdaq:ACST

ACST Rankings

ACST Stock Data

28.48M
6.29M
16.02%
12.13%
0.02%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States of America
PRINCETON

About ACST

acasti pharma, inc., a subsiduary of neptune technologies & bioressources, is a quebec-based biopharmaceutical dedicated in advancing a proprietary portfolio based on marine phospholipids. our products can be used in prescription, medical food and over-the-counter applications, either as a stand-alone, or, as a fixed-dose combination to exisitng productrs, for the prevention and treatment of cardiometabolic disorders.